On 5 March 2020, Professor Sir Mark Caulfield, Chief Scientist at Genomics England, delivered the keynote talk at St Bartholomew’s Great Hall for the Precision Medicine Leadership event co-hosted by Queen Mary University London (QMUL).
The event set out to explore how collaboration can enable and advance precision medicine, showcasing new developments in the field from academia and industry. The event fostered networking opportunities between delegates who attended from more than 30 companies spanning pharma, biotech, data analytics, intellectual property law, medical writing, funding bodies and life sciences consulting.
Professor Sir Mark Caulfield gave insights into the growing importance of precision medicine in the UK, and detailed Genomics England’s contribution towards this, including: the ground-breaking 100,000 Genomes Project, collaboration on the NHS Genomic Medicine Service, enabling the UK Government’s Life Sciences ambition of sequencing 5 million genomes in 5 years.
Professor Sir Mark Caulfield spoke alongside Professor Claude Chelala of Bart’s Cancer Institute and Professor David van Heel of the QMUL Blizard Institute. Industry talks were given by AstraZeneca, precisionlife, Celyad, Cerba Research and Roche. The event concluded with a dynamic panel discussion involving Professor Rakesh Uppal of Bart’s Life Sciences and Jane Theaker, CEO at Kinomica Ltd., a spin-out company of QMUL.
You can watch a summary video of the event here (external link to LinkedIn).